• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus.利拉鲁肽治疗对2型糖尿病患者氧化应激和心钠素水平的影响。
Endocrine. 2014 Dec;47(3):962-4. doi: 10.1007/s12020-014-0246-6. Epub 2014 Apr 3.
2
Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.利拉鲁肽可降低2型糖尿病患者的氧化应激水平并恢复血红素加氧酶-1和胃饥饿素水平：一项前瞻性初步研究。
J Clin Endocrinol Metab. 2015 Feb;100(2):603-6. doi: 10.1210/jc.2014-2291. Epub 2014 Nov 13.
3
Liraglutide.利拉鲁肽。
Nat Rev Drug Discov. 2010 Apr;9(4):267-8. doi: 10.1038/nrd3148.
4
Treatment of type 2 diabetes with incretin-based therapies.使用基于肠促胰岛素的疗法治疗2型糖尿病。
Lancet. 2009 Feb 7;373(9662):438-9. doi: 10.1016/S0140-6736(08)61247-7. Epub 2008 Sep 24.
5
Liraglutide (Victoza) for type 2 diabetes.利拉鲁肽（维达列汀）用于2型糖尿病。
Med Lett Drugs Ther. 2010 Apr 5;52(1335):25-7.
6
[Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].人胰高血糖素样肽-1类似物利拉鲁肽（维达列汀（®））的药理学和临床概况
Nihon Yakurigaku Zasshi. 2010 Oct;136(4):233-41. doi: 10.1254/fpj.136.233.
7
Treatment evaluation of liraglutide in type 2 diabetes.利拉鲁肽治疗2型糖尿病的疗效评估
Expert Opin Biol Ther. 2012 Nov;12(11):1551-6. doi: 10.1517/14712598.2012.716823. Epub 2012 Aug 16.
8
[Liraglutide in polycystic ovary syndrome].[利拉鲁肽治疗多囊卵巢综合征]
Med Clin (Barc). 2014 Sep 15;143(6):283-4. doi: 10.1016/j.medcli.2013.11.016. Epub 2014 Jan 21.
9
Liraglutide therapy in obese people with type 2 diabetes - experience of a weight management centre.利拉鲁肽治疗肥胖的2型糖尿病患者——一家体重管理中心的经验
Eur J Intern Med. 2014 Mar;25(3):e38-9. doi: 10.1016/j.ejim.2013.12.009. Epub 2014 Jan 10.
10
Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.利拉鲁肽诱导的身体成分变化与肥胖2型糖尿病患者血浆心钠素水平的改变有关。
Cardiovasc Diabetol. 2014 Feb 5;13:36. doi: 10.1186/1475-2840-13-36.

引用本文的文献

1
The Impact of Liraglutide, a GLP-1 Receptor Agonist, on High Glucose-Induced Inflammation, Apoptosis, Oxidative Stress, and NLRP3 Signaling.胰高血糖素样肽-1受体激动剂利拉鲁肽对高糖诱导的炎症、细胞凋亡、氧化应激和NLRP3信号传导的影响
Cell Biochem Biophys. 2025 Apr 11. doi: 10.1007/s12013-025-01742-1.
2
Incretin-Based Therapies: A Promising Approach for Modulating Oxidative Stress and Insulin Resistance in Sarcopenia.基于肠促胰岛素的疗法：调节肌肉减少症中氧化应激和胰岛素抵抗的一种有前景的方法。
J Bone Metab. 2024 Nov;31(4):251-263. doi: 10.11005/jbm.24.739. Epub 2024 Nov 4.
3
Label-free quantitative proteomic profiling reveals differential plasma protein expression in patients with obesity after treatment with liraglutide.无标记定量蛋白质组学分析揭示了利拉鲁肽治疗后肥胖患者血浆蛋白表达的差异。
Front Mol Biosci. 2024 Sep 11;11:1458675. doi: 10.3389/fmolb.2024.1458675. eCollection 2024.
4
Safety and Efficacy of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.利拉鲁肽对糖尿病患者心血管结局的安全性和有效性：一项随机对照试验的荟萃分析
Cureus. 2023 Sep 17;15(9):e45421. doi: 10.7759/cureus.45421. eCollection 2023 Sep.
5
Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms.用胰高血糖素样肽-1 受体激动剂预防中风：潜在机制的综合综述。
Cardiovasc Diabetol. 2022 Nov 15;21(1):242. doi: 10.1186/s12933-022-01686-3.
6
Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options.糖尿病中的冠状动脉微血管功能障碍：发病机制与潜在治疗选择
Biomedicines. 2022 Sep 14;10(9):2274. doi: 10.3390/biomedicines10092274.
7
The Prognostic Value of Derivatives-Reactive Oxygen Metabolites (d-ROMs) for Cardiovascular Disease Events and Mortality: A Review.衍生反应性氧代谢产物（d-ROMs）对心血管疾病事件和死亡率的预后价值：综述
Antioxidants (Basel). 2022 Aug 9;11(8):1541. doi: 10.3390/antiox11081541.
8
Sex differences in oxidative stress level and antioxidative enzymes expression and activity in obese pre-diabetic elderly rats treated with metformin or liraglutide.二甲双胍或利拉鲁肽治疗的肥胖糖尿病前期老年大鼠氧化应激水平及抗氧化酶表达和活性的性别差异
Croat Med J. 2021 Jun 30;62(3):215-226. doi: 10.3325/cmj.2021.62.215.
9
Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms.基于肠促胰岛素的药物的抗氧化潜力：分子机制综述。
Oxid Med Cell Longev. 2021 Apr 27;2021:9959320. doi: 10.1155/2021/9959320. eCollection 2021.
10
Liraglutide, a glucagon-like peptide-1 analog, inhibits high glucose-induced oxidative stress and apoptosis in neonatal rat cardiomyocytes.利拉鲁肽，一种胰高血糖素样肽-1类似物，可抑制高糖诱导的新生大鼠心肌细胞氧化应激和细胞凋亡。
Exp Ther Med. 2019 May;17(5):3734-3740. doi: 10.3892/etm.2019.7388. Epub 2019 Mar 13.

本文引用的文献

1
Beneficial effects of liraglutide on adipocytokines, insulin sensitivity parameters and cardiovascular risk biomarkers in patients with Type 2 diabetes: a prospective study.利拉鲁肽对2型糖尿病患者脂肪细胞因子、胰岛素敏感性参数及心血管风险生物标志物的有益影响：一项前瞻性研究。
Diabetes Res Clin Pract. 2014 Apr;104(1):92-6. doi: 10.1016/j.diabres.2014.01.019. Epub 2014 Jan 25.
2
Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature.二肽基肽酶-4抑制剂和胰高血糖素样肽-1受体激动剂在2型糖尿病合并肾或肝功能损害患者中的药代动力学、安全性及疗效：文献系统评价
Endocrine. 2014 Aug;46(3):406-19. doi: 10.1007/s12020-014-0179-0. Epub 2014 Feb 8.
3
Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients.利拉鲁肽诱导的身体成分变化与肥胖2型糖尿病患者血浆心钠素水平的改变有关。
Cardiovasc Diabetol. 2014 Feb 5;13:36. doi: 10.1186/1475-2840-13-36.
4
Effects of incretin-based therapy in patients with heart failure and myocardial infarction.基于肠促胰岛素的疗法对心力衰竭和心肌梗死患者的影响。
Endocrine. 2014 Sep;47(1):21-8. doi: 10.1007/s12020-014-0175-4. Epub 2014 Feb 4.
5
Serum prolidase enzyme activity and oxidative stress levels in patients with diabetic neuropathy.糖尿病神经病变患者的血清脯氨酰肽酶活性和氧化应激水平
Endocrine. 2014 Sep;47(1):146-51. doi: 10.1007/s12020-013-0136-3. Epub 2013 Dec 18.
6
Cardiovascular risk factors in a patient with diabetes mellitus and coronary artery disease: therapeutic approaches to improve outcomes: perspectives of a preventive cardiologist.糖尿病合并冠心病患者的心血管危险因素：改善预后的治疗方法：预防心脏病专家的观点。
Am J Cardiol. 2012 Nov 6;110(9 Suppl):43B-49B. doi: 10.1016/j.amjcard.2012.08.033.
7
Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes.每日一次注射利拉鲁肽（一种人胰高血糖素样肽-1类似物）对2型糖尿病患者心血管风险生物标志物的有益作用。
Diabet Med. 2008 Sep;25(9):1129-31. doi: 10.1111/j.1464-5491.2008.02484.x.
8
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.胰高血糖素样肽-1受体激动剂利拉鲁肽激活细胞保护途径并改善小鼠实验性心肌梗死后的结局。
Diabetes. 2009 Apr;58(4):975-83. doi: 10.2337/db08-1193. Epub 2009 Jan 16.
9
An easy and reliable automated method to estimate oxidative stress in the clinical setting.一种在临床环境中评估氧化应激的简便可靠的自动化方法。
Methods Mol Biol. 2008;477:31-9. doi: 10.1007/978-1-60327-517-0_3.
10
Lipid peroxides in type 2 diabetic patients with neuropathy.2型糖尿病神经病变患者中的脂质过氧化物
Res Commun Mol Pathol Pharmacol. 2005;117-118:5-12.

Effects of treatment with liraglutide on oxidative stress and cardiac natriuretic peptide levels in patients with type 2 diabetes mellitus.

作者信息

Okada Kenta, Kotani Kazuhiko, Yagyu Hiroaki, Ando Akihiko, Osuga Jun-Ichi, Ishibashi Shun

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan,

出版信息

Endocrine. 2014 Dec;47(3):962-4. doi: 10.1007/s12020-014-0246-6. Epub 2014 Apr 3.

DOI:10.1007/s12020-014-0246-6
PMID:24696097
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4239782/
Abstract
摘要